TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06796075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mom♥Health
Description: 12-week intervention involving 1) weekly phone calls to mothers regarding education and counseling related to heart healthy lifestyle, as well as strategies for stress reduction; 2) referral to clinical care for identified needs (e.g., elevated blood pressure); and 3) referral to available social resources (e.g., food pantry for identified food insecurity).
Study: NCT05597176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Cord Injury Exercise Group
Description: Participants will have an initial accommodation period of 4 weeks, during which four 10-minute exercise bouts/day will be interspersed with 5 minutes of rest. The bouts will gradually increase until at least continuous 40-minute sessions. The remaining 12-week intervention will be set at 70% max heart rate for a total of 16 weeks.
Study: NCT06795737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation
Description: The experimental group's protocol consists of two stages: in-hospital Phase I and post-discharge self-training. For Phase I, cardiac and rehab specialists assess NYHA classification, muscle strength, and mobility to create an exercise plan, supervised by therapists and nurses. Phase II involves twice-weekly outpatient rehab for 24 sessions and weekly remote guidance with WeChat and wristbands to track vitals, totaling 12 remote sessions. Exercise prescriptions are customized based on 6MWTD outcomes, with ongoing support from rehab staff and nurses.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Conventional rehabilitation
Description: Health Education: Nurses provide manuals on heart failure causes, treatment, diet, exercise (detailing frequency, intensity, duration, types, and safety), and self-monitoring to control group patients.~Outpatient Follow-up: Post-discharge, heart failure patients have follow-ups at 2 weeks, 1 month, 2 months, and 3 months. A multidisciplinary team of doctors, pharmacists, and nurses handles these, with doctors for assessment, pharmacists for medication education, and nurses for self-care assessment and education.
Study: NCT06796907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK5733584
Description: GSK5733584 will be administered intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK5733584
Description: GSK5733584 will be administered intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK5733584
Description: GSK5733584 will be administered intravenously (IV).
Study: NCT05678816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy prgramme for rehabilitation of stroke patients
Description: physiotherapy prgramme for rehabilitation of stroke patients which include:~* Passive stretching exercise, strengthening exercise.~* Postural control and balance exercise from different positions as quadruped, kneeling, sitting and standing.~* Gait training.
Study: NCT06796907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK5733584
Description: GSK5733584 will be administered intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticancer therapy 1
Description: Anticancer therapy 1 will be administered IV.
Study: NCT05678816

Intervention type: OTHER
Group type: OTHER
Intervention: physiotherapy prgramme for rehabilitation of stroke patients
Description: physiotherapy prgramme for rehabilitation of stroke patients which include:~* Passive stretching exercise, strengthening exercise.~* Postural control and balance exercise from different positions as quadruped, kneeling, sitting and standing.~* Gait training.
Study: NCT06796907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticancer therapy 1
Description: Anticancer therapy 1 will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticancer therapy 1
Description: Anticancer therapy 1 will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticancer therapy 2
Description: Anticancer therapy 2 will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticancer therapy 2
Description: Anticancer therapy 2 will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticancer therapy 2
Description: Anticancer therapy 2 will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticancer therapy 3
Description: Anticancer therapy 3 will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticancer therapy 4
Description: Anticancer therapy 4 will be administered IV.
Study: NCT06461988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab Step up dosing:~C1D1: 10 mcg/kg C1D3a: 60 mcg/kg C1D5a: 400 mcg/kg C1D15: 800 mcg/kg~Talquetamab 800 mg/kg SC Q4W in 28-day cycle for Cycles 2-13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab and Lenalidomide
Description: Lenalidomide 10 mg, 3 weeks on 1 week off, until PD/ intolerance, C2-13 (Lenalidomide 5 mg for creatinine clearance 30-60 ml/min)
Study: NCT06797583

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Photobiomodulation (TPBM)
Description: CytonBrite, 1064nm LED

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Photobiomodulation (TPBM)
Description: CytonBrite, 1064nm LED

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial photobiomodulation (TPBM)
Description: Sham condition using a randomized block design involving 2 (TPBM): 1(sham) randomization.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial photobiomodulation (TPBM)
Description: Sham condition using a randomized block design involving 2 (TPBM): 1(sham) randomization.
Study: NCT06793228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nanocrystalline Megestrol Acetate
Description: Nanocrystalline Megestrol Acetate + Tislelizumab+ Chemotherapy (Carboplatin + Etoposide)
Study: NCT06509997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG003 combined with Dalpicicilip
Description: MRG003, intravenous infusion, D1, once every 3 weeks; Dalpicicilip, taking orally, D1-21, once every 4 weeks, maintain use until progression or emergence of intolerable toxicity.
Study: NCT05156099

Intervention type: DEVICE
Intervention: Ultrasound Scanning
Description: The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.

Intervention type: DEVICE
Intervention: Ultrasound Scanning
Description: The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.

Intervention type: DEVICE
Intervention: Ultrasound Scanning - 2 months later
Description: The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.

Intervention type: DEVICE
Intervention: Ultrasound Scanning - 2 months later
Description: The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.
Study: NCT05317715

Intervention type: OTHER
Group type: OTHER
Intervention: Group A, who will complete a questionnaire before receiving information about intrauterine devices
Description: Group A will complete a questionnaire before receiving information about intrauterine devices and a demonstration of insertion/removal on a plastic dummy uterus.

Intervention type: OTHER
Group type: OTHER
Intervention: Group B who will answer a questionnaire after having the information about the intrauterine devices
Description: Group B will complete a questionnaire after receiving information about IUDs and a demonstration of insertion/removal on a plastic dummy uterus.
Study: NCT04985500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block
Description: peripheral nerve block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PIF block
Description: peripheral nerve block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound guidance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound guidance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 10-20 mL of 0.25% bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 10-20 mL of 0.25% bupivacaine
Study: NCT06486493

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional medical treatment by their physicians, following the Clinical Practice Guideline for the Prevention and Diagnosis of Overweight and Obesity in Children and Adolescents (SS-025-08) and the Guideline for the Diagnosis, Treatment, and Prevention of Overweight and Obesity in Adults (IMSS 46-08), over six months, with a follow-up of 18 months post-intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional medical treatment by their physicians, following the Clinical Practice Guideline for the Prevention and Diagnosis of Overweight and Obesity in Children and Adolescents (SS-025-08) and the Guideline for the Diagnosis, Treatment, and Prevention of Overweight and Obesity in Adults (IMSS 46-08), over six months, with a follow-up of 18 months post-intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Playful Family Education Strategy
Description: Workshop based on national and international guidelines for managing overweight and obesity in school-aged children, by the Food and Agriculture Organization (FAO). Monthly sessions over six months for parents and children, followed by an 18-month post-intervention follow-up.~For parents:~* First session focuses on raising awareness about childhood obesity through counseling and nutritional advice, promoting water consumption over sugary drinks.~* Subsequent sessions use 'case study' technique to discuss common food and nutrition challenges.~For children:~* Sessions follow the 'Nutritional Guidance Intervention Guide' by the National System for Integral Family Development (DIF).~* First session encourages healthy eating habits through activities and educational games.~* Later sessions emphasize healthy eating patterns and physical activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reinforced Playful Family Education Strategy
Description: The previosuly created and INDAUTOR registered workshop, will be reinforced through two-week technological algorithms, such as videogames, educational videos, and digital challenges, for the children, that they must complete through their smartphone of tablet. Followed by an 18-month post-intervention follow-up.
Study: NCT06793228

Intervention type: DRUG
Group type: OTHER
Intervention: Nanocrystalline Megestrol Acetate
Description: Nanocrystalline Megestrol Acetate + Tislelizumab+ Chemotherapy (Carboplatin + Etoposide)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab combined with chemotherapy (Carboplatin + Etoposide)

Intervention type: DRUG
Group type: OTHER
Intervention: PTOC
Description: Nanocrystalline Megestrol Acetate+PD-(L)1 inhibitors+chemotherapy
Study: NCT06795945

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TPG1
Description: * Thymus Nuclear Extract Dose 1 (860 mg \[2 tablets, 2x/day; total 4 tablets per day\])~* Placebo (6 tablets, 2x/day; total 12 tablets per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TPG2
Description: * Thymus Nuclear Extract Dose 2 (2150 mg \[5 tablets, 2x/day; total 10 tablets per day\])~* Placebo (3 tablets, 2x/day; total 6 tablets per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TPG3
Description: Thymus Nuclear Extract Dose 3 (3440 mg \[8 tablets, 2x/day; total 16 tablets per day\])

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (8 tablets, 2x/day; total 16 tablets per day)
Study: NCT06796998

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab will be administered via subcutaneous (SC) injection using a step-up dosing schedule as follows:~* Cycle 1, Day 1: 0.16 mg~* Cycle 1, Day 8: 0.8 mg~* Cycle 1, Day 15: 3 mg~* Cycle 1, Day 22: 48 mg~* Cycles 2 to 3, Days 1, 8, 15 and 22: 48 mg~* Cycles 4 to 9, Days 1 and 15: 48 mg~* Cycles 10 to 12; Day 1: 48 mg
Study: NCT06796361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketanserin 40mg plus Psilocybin 40mg
Description: 40mg Ketanserin oral will be administered followed by 40mg Psilocybin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40mg Psilocybin
Description: Placebo oral followed by 40mg Psilocybin one hour later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg Psilocybin
Description: Placebo oral followed by 20mg Psilocybin one hour later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg Psilocybin
Description: Placebo oral followed by 10mg Psilocybin oral one hour later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5mg Psilocybin
Description: Placebo oral followed by 5mg Psilocybin one hour later

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo followed by oral Placebo one hour later
Study: NCT06796491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Isometric relaxation
Description: Group A will receive Post Isometric Relaxation (PIR) Patient applied the sub-maximal contraction almost 20%. Isometric contraction was held for 10 seconds and then slight stretch for 30 seconds was maintained.4 contractions per treatment with 3 seconds rest between each contraction. This protocol continues 3 days/week for 4 weeks conventional treatment Hot pack for 10 minutes Pelvic bridging: The subjects will be asked to lie supine and with knee flexed and then raise the pelvis upward till the comfort then hold that position for 5 sec and repetitions were 10 times Cat and camel: The subjects will be requested to prone kneel and then take a deep breath from nose while making hump in the back (cat) and breathe out from mouth while curving the spine (camel) for 5 second 10 times repetitions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post Facilitation stretch
Description: Group B will receive Post Facilitation Stretch (PFS) Isometric contraction was held for 10 seconds and then slight stretch for 30 seconds was maintained. 4 contractions per treatment with 3 seconds rest between each contraction. This protocol continues 3 days/week 4 weeks. for hamstring flexibility conventional treatment Hot pack for 10 minutes Pelvic bridging: The subjects will be asked to lie supine and with knee flexed and then raise the pelvis upward till the comfort then hold that position for 5 sec and repetitions were 10 times Cat and camel: The subjects will be requested to prone kneel and then take a deep breath from nose while making hump in the back (cat) and breathe out from mouth while curving the spine (camel) for 5 second 10 times repetitions
Study: NCT06795191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Mesylate
Description: 22.5 mg in a prefilled, ready-to-use, long-acting formulation
Study: NCT06793592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally informed recruitment message
Description: Study participants will receive a behaviorally informed recruitment message that highlights an employer value proposition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally informed recruitment message
Description: Study participants will receive a behaviorally informed recruitment message that highlights an employer value proposition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally informed recruitment message
Description: Study participants will receive a behaviorally informed recruitment message that highlights an employer value proposition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally informed recruitment message
Description: Study participants will receive a behaviorally informed recruitment message that highlights an employer value proposition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally informed recruitment message
Description: Study participants will receive a behaviorally informed recruitment message that highlights an employer value proposition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally informed recruitment message
Description: Study participants will receive a behaviorally informed recruitment message that highlights an employer value proposition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally informed recruitment message
Description: Study participants will receive a behaviorally informed recruitment message that highlights an employer value proposition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally informed recruitment message
Description: Study participants will receive a behaviorally informed recruitment message that highlights an employer value proposition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally informed recruitment message
Description: Study participants will receive a behaviorally informed recruitment message that highlights an employer value proposition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simplified direct message with no employer value proposition
Description: Study participants will receive a simplified message that does not highlight any specific employer value proposition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No message
Description: Study participants will not receive a recruitment message.
Study: NCT06350136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: With Tele-Nursing
Description: no With Tele-Nursing
Study: NCT06793748

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PEP-TISSEEL
Description: Purified Exosome Product (PEP™) and Fibrin Sealant (TISSEEL® VH SD Kit) (Biologic) (PEP-TISSEEL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TISSEEL Fibrin Sealant KIT
Description: Fibrin Sealant (TISSEEL® VH SD Kit)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PEP-TISSEEL
Description: Purified Exosome Product (PEP™) and Fibrin Sealant (TISSEEL® VH SD Kit) (Biologic) (PEP-TISSEEL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TISSEEL Fibrin Sealant KIT
Description: Fibrin Sealant (TISSEEL® VH SD Kit)
Study: NCT06793644

Intervention type: DRUG
Intervention: Immunofluorescence Imaging
Description: Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.

Intervention type: DRUG
Intervention: Immunofluorescence Imaging
Description: Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
Study: NCT04899544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Pivotal Response Treatment (PRT Intervention (PRT-H)
Description: Pivotal Response Treatment in home environment.
Study: NCT06563479

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FMISO-PET Scan
Description: Patients will undergo 18F-FMISO scan (only 1 injection) that occurs at week two of radiation treatment, typically day 10 but a window of 8-10 radiation treatment days\* after start of radiation is allowed.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FMISO-PET Scan
Description: Patients will undergo 18F-FMISO scan (only 1 injection) that occurs at week two of radiation treatment, typically day 10 but a window of 8-10 radiation treatment days\* after start of radiation is allowed.
Study: NCT06794801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Coated Autoperfusion Balloon Dilatation Catheter（DCAB）
Description: In the experimental arm, under the assessment and guidance of IVUS-OCT, STEMI patients with successfully prepared lesions will be treated with a drug-coated autoperfusion balloon dilatation catheter (DCAB). Successful lesion preparation is defined as post-pretreatment residual stenosis ≤ 30%, no type C dissections, intravascular imaging confirming no significant residual plaque burden at the dissection site, no transverse expansion \> 60°, no longitudinal expansion \> 2 mm, no dissection involving the media or adventitia, and no location at the stent distal end. There should be no hematoma and no significant thrombus (TIMI thrombus burden grade ≤ 2). If the angiographic and intravascular imaging results after DCAB treatment are unsatisfactory, an emergency drug-eluting stent (DES) will be implanted.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Drug coated balloon (DCB)
Description: In the control arm, under the assessment and guidance of IVUS-OCT, STEMI patients with successful lesion preparation (residual stenosis ≤ 30%, no type C dissections, no significant residual plaque burden, no dissection involving the media or adventitia, no transverse expansion \> 60°, no longitudinal expansion \> 2 mm, no location at the stent distal end, no hematoma, TIMI thrombus burden grade ≤ 2) will be treated with a conventional DCB coated with 3 μg/mm2 paclitaxel. If angiographic and intravascular imaging results are unsatisfactory, a bailout DES will be implanted.
Study: NCT06795529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Intervention, TARGET-PC
Description: Palliative care intervention focused on eliciting patients' goals and values to facilitate discussion and documentation of health care preferences.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Oncology clinicians will receive an EPIC message to encourage them to discuss and document their patients' health care preferences.